Safety and Efficacy Study of LX103 Treatment of X-Linked Retinoschisis (XLRS)
An Open Label Dose Escalation Clinical Trial to Evaluate the Safety and the Efficacy of LX103 in Patients With X-Linked Retinoschisis (XLRS)
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
12 participants
Dec 13, 2022
INTERVENTIONAL
Conditions
Summary
The goal of this study is to evaluate the safety and efficacy of LX103 treatment of X-linked retinoschisis. This study will enroll subjects aged ≥ 6 years old to receive a single unilateral intravitreal (IVT) injection of LX103 to evaluate its safety and efficacy.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Qualified subjects will receive a single unilateral intravitreal injection of LX103 at Day 0 in the trial.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05814952